0001356576-20-000037.txt : 20200611 0001356576-20-000037.hdr.sgml : 20200611 20200611080751 ACCESSION NUMBER: 0001356576-20-000037 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20200609 ITEM INFORMATION: Completion of Acquisition or Disposition of Assets ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200611 DATE AS OF CHANGE: 20200611 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SUPERNUS PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001356576 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35518 FILM NUMBER: 20956218 BUSINESS ADDRESS: STREET 1: 9715 KEY WEST AVENUE CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 301-838-2500 MAIL ADDRESS: STREET 1: 9715 KEY WEST AVENUE CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: SUPERNUS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20060317 8-K 1 supn-20200609.htm 8-K supn-20200609
false000135657600013565762020-06-092020-06-09


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): June 9, 2020
 
Supernus Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)

Delaware
001-3551820-2590184
(State or other jurisdiction of incorporation or organization)
(Commission File Number)
(I.R.S. Employer Identification No.)
9715 Key West Ave
Rockville
MD
20850
(Address of Principal Executive Offices)
(Zip Code)

 
Registrant’s telephone number, including area code: (301) 838-2500
 
Not Applicable
(Former name or former address, if changed since last report.)

  Securities registered pursuant to Section 12(b) of the Exchange Act
Title of each classTrading SymbolName of each exchange on which registered
Common Stock, $0.001 par value per shareSUPNThe Nasdaq Global Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐




Item 2.01 Completion of Acquisition or Disposition of Assets.

On June 9, 2020, Supernus Pharmaceuticals, Inc. (the “Company”) completed its previously announced acquisition of all of the outstanding equity of USWM Enterprises, LLC (“USWM Enterprises”), comprising the entire issued share capital of USWM Enterprises (the “Transaction”), pursuant to a Sale and Purchase Agreement with US WorldMeds Partners, LLC (“US WorldMeds”), dated April 28, 2020 (the “Agreement”). At the closing of the Transaction, the Company paid US WorldMeds $300 million in cash. Under the terms of the Agreement, the Company acquired the central nervous system portfolio of US WorldMeds, and specifically, the right to further develop and commercialize Apokyn®, Xadago® and the Apomorphine Infusion Pump in the United States and Myobloc® worldwide (the “Products”). The Company will be required to make additional cash payments of up to $230 million to US WorldMeds upon the achievement of certain commercial milestones related to the sale and development of the Products. The terms of the Transaction as set forth in the Agreement were previously disclosed in the Company’s Current Report on Form 8-K filed on May 4, 2020.

The foregoing description of the terms of the Agreement and is only a summary, does not purport to be complete and is qualified in its entirety by reference to the Agreement, which the Company intends to file as an exhibit to the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2020. Unless otherwise defined herein, the capitalized terms used above shall have the same meaning ascribed to them in the Agreement.

Item 8.01                                           Other Events.

On June 9, 2020, the Company issued a press release announcing the closing of the Transaction. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 9.01                                          Financial Statements and Exhibits.
 
(a) Financial Statements of Business Acquired

This Current Report on Form 8-K will be supplemented by amendment to provide the required financial statements not later than 71 days after the date that this Current Report on Form 8-K was required to be filed pursuant to Item 2.01.

(b) Pro Forma Financial Information

This Current Report on Form 8-K will be supplemented by amendment to provide the required pro forma financial information not later than 71 days after the date that this Current Report on Form 8-K was required to be filed pursuant to Item 2.01.

(d)                                Exhibits

Exhibit 99.1 — Press Release Dated June 9, 2020, furnished as an Exhibit pursuant to Item 8.01 hereof.

Exhibit 104 — The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.


2

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 

 SUPERNUS PHARMACEUTICALS, INC.
  
DATED: June 11, 2020By:/s/ Gregory S. Patrick
  Gregory S. Patrick
  Senior Vice-President and Chief Financial Officer

3
 EX-99.1 2 ex99106-09x2020.htm EX-99.1 Document

              Exhibit 99.1
logoa051.jpg      
 

Supernus Completes Acquisition of CNS Portfolio from US WorldMeds

Creates leading CNS portfolio with five marketed products, two product candidates in late-stage development, and robust pipeline

ROCKVILLE, Md., June 9, 2020 - Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced the closing of the acquisition of the CNS portfolio of US WorldMeds, a privately-held biopharmaceutical company. This transaction builds on Supernus’ experience in CNS diseases and expands its marketing and development efforts into Parkinson’s disease.

“This acquisition significantly expands our business in CNS and increases and diversifies our revenue and earnings streams, while continuing to maintain a strong balance sheet,” said Jack Khattar, President and CEO of Supernus. “We welcome our US WorldMeds’ colleagues who are joining Supernus and look forward to working with them on building our leadership position in CNS across numerous diseases.”

For additional details relating to the acquisition, please see the press release issued by Supernus on April 28, 2020 announcing the acquisition.

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company markets Trokendi XR® (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy, Oxtellar XR® (extended-release oxcarbazepine) for the treatment of epilepsy, Apokyn® (apomorphine hydrochloride injection) for the acute treatment of hypomobility in advanced Parkinson’s disease (PD), Myobloc® (rimabotulinumtoxinB) for the treatment of cervical dystonia and treatment of chronic sialorrhea in adults, and Xadago® (safinamide) as an adjunctive treatment to levodopa/carbidopa in PD patients with hypomobility. The Company is also developing several product candidates to address large market opportunities in the CNS market, including SPN-812 for the treatment of ADHD, apomorphine infusion pump for hypomobility in PD, SPN-820 (NV-5138) for treatment-resistant depression, and SPN-817 for the treatment of epilepsy.

APOKYN Pen and apomorphine infusion pump product candidate are under a license from Britannia Pharmaceuticals Limited
XADAGO is under a license from Zambon S.p.A
All trademarks are the property of their respective owners

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements do not convey historical information, but relate to predicted or potential future events that are based upon management's current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In addition to the factors mentioned in this press release, such risks and uncertainties include, but are not limited to, the Company’s ability to successfully incorporate and integrate the acquired products and product candidate, technologies, sales force and organization into its current infrastructure, the Company’s ability to achieve the anticipated revenues and benefits from the acquired products; the Company’s ability to sustain and increase its profitability; the Company’s ability to raise sufficient capital to fully implement its corporate strategy; the implementation of the Company’s corporate strategy; the Company’s future financial performance and projected expenditures; the Company’s ability to increase the number of prescriptions written for each of its products; the Company’s ability to increase its net revenue; the Company’s ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies; the Company’s product research and development activities, including the timing and progress of the Company’s clinical trials, and projected expenditures; the Company’s ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize the Company’s product candidates; the Company’s ability to protect its intellectual property and operate its business without infringing upon the intellectual property rights of others; the Company’s expectations regarding federal, state and foreign regulatory requirements;


the therapeutic benefits, effectiveness and safety of the Company’s product candidates; the accuracy of the Company’s estimates of the size and characteristics of the markets that may be addressed by its product candidates; the Company’s ability to increase its manufacturing capabilities for its products and product candidates; the Company’s projected markets and growth in markets; the Company’s product formulations and patient needs and potential funding sources; the Company’s staffing needs; and other risk factors set forth from time to time in the Company’s filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. The Company undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events.

CONTACTS:
Jack A. Khattar, President and CEO
Gregory S. Patrick, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591

or

INVESTOR CONTACT:
Peter Vozzo
Westwicke, an ICR Company
Office: (443) 213-0505
Mobile: (443) 377-4767
Email: peter.vozzo@westwicke.com

 EX-101.SCH 3 supn-20200609.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 supn-20200609_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 5 supn-20200609_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 supn-20200609_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Written Communications Written Communications Pre-commencement Tender Offer Pre-commencement Tender Offer Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, City or Town Entity Address, City or Town Soliciting Material Soliciting Material Entity Address, Address Line One Entity Address, Address Line One Security Exchange Name Security Exchange Name City Area Code City Area Code Cover [Abstract] Cover [Abstract] Entity Central Index Key Entity Central Index Key Entity Tax Identification Number Entity Tax Identification Number Entity Filer Name Entity File Number Document Type Document Type Entity Emerging Growth Company Entity Emerging Growth Company Title of 12(b) Security Title of 12(b) Security Amendment Flag Amendment Flag Local Phone Number Local Phone Number Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Trading Symbol Trading Symbol Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name EX-101.PRE 7 supn-20200609_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 8 logoa051.jpg begin 644 logoa051.jpg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�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end XML 9 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 1 95 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Page Sheet http://www.supernus.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports supn-20200609.htm ex99106-09x2020.htm supn-20200609.xsd supn-20200609_cal.xml supn-20200609_def.xml supn-20200609_lab.xml supn-20200609_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true true EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 supn-20200609_htm.xml IDEA: XBRL DOCUMENT 0001356576 2020-06-09 2020-06-09 false 0001356576 8-K 2020-06-09 Supernus Pharmaceuticals, Inc. DE 001-35518 20-2590184 9715 Key West Ave Rockville MD 20850 301 838-2500 Common Stock, $0.001 par value per share SUPN NASDAQ false false false false false ZIP 12 0001356576-20-000037-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001356576-20-000037-xbrl.zip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

G$A' #\""=087 M!S*1%%LW5LK76.OV@7!2Q^)GN%3\,I;>2UL3?:N%1@:@)\!MX03BG^++>$0]S!5[5S!8K48'H? M'SCV"-4F$9W=T#.J8L8;/)2^DEF]9)0Y&IC"?Z'SK**Y2Z#TA19+I>U5=%1J M:(IY.6T=VI 3U];<*!!#\=LEYI2=K0.Q 5*'*RJN5]CVT,O*%%US<[8_%,K' MTT3>P3YHD.J1E<052?DG^JD<539WTYJX@.PDD?:Y[ MY>9FFE7"9&Y28_,QJ3*>QM9$8\ )1DU[I/B-GXO44:%?R1W/"4! YUH/Z6R M*.-;R>QC:3\6&_T3L*;W4S-(3%3I874J08(+X*5(O;G3V?=++(D0,P9%C*"9 M3,O@P@=+QNA".D);E##&CI4,JA4)<7Q:_IN,Y,P^A1 A/G)F' ML,-+ N2"V0.[HO!R[00.1M78(DQ.M*W(4 [#A%*QN?!YC=I\4G ;N^J?UW?; MG<7^/#KYZ01.F<.!SH9@#SLL*WE'_XI??ST5?96S^BWHY.C'R\H,Q9:^R^9#FB* M:.2-H]4R["A):"2*%66EXWA6W4!9)%.8PC31;I>K4'',!'WIZ<'.Z\/_2\\% M?@A\NWX&\LWUR /;E/ K:>222/-0]HCC<@56KAHXZDGI #=S />*LGBG2F9S MPWH_#-[B2D6%#57^#']&DD>02P6AJ3B*N&JV]_9ZW&2(;]\+CXW(C*=Q[59- M!13TZ.W4.U%W<+<,/'T ]LE$GI@+F1#KB([%4)YS Z[AT4;%L/ %P$O#(01[ M#' ,YH$D/E;DT @NE"/>^%LGH++E&?V.4,T;N04*D@A7#(AIT-Y6NYLPI]$1 MAJ6ADNWF[2)3)"!Z$@P03,074 K>IIY.M\9Z.$3A(-)EH2_&8*X:0'B$W88%609A:"#&,,Z3'2='SD9!*0&@6AQHX Q\^R''BA YW&5'$%@*S$M ^1 M@,47U9?16*O;4C]X)-(Y/S0L#QN"B@.5J2%M4D9N@2EOUGM[!U_VE0O'$7-G M':P\I$!^N?)%HL#1";#%< B5^6FGS.D@FCXK8T'']DQ>V#VSN, W^#.:VV:V M4CXX?WNT^7,2'J\M8X6@=. M/D!R067"?&1US@DM)JA+*!#,Y!1B3"M*1[\\7 ]"E"E?@>)%-_,I>H!GZ0TZ M"<(H866I(G'QA>.D+F$G(VK/&!P?'/>;1*.[A-20L//3[$I*/26Z[N\XR=:3&J0SG=0LJ(B\TRT* ?L66> M:E\YX_R)X%L5*3"1VOUT&G3!]C3 \,H#9/1-70Z1G/LRF9\Q/#[3+Z1U"GXWXQE3S MH0P<$F,B+:PK9#CEN@H'?Z+=I3;8[FW$FQ5"YL3-1,UFD.Y6C<_/4CZ??'CH MQ7.]ES>X,:.^FE2##/8K\K@BKW.#R6*>'=K3D*IS-8Q QTC;J$CIN"DB0ZGN ML#B6"[\JJMIV_E[ZU$2!SH(M<6>[YZ586V3S%\)6JW H]=*A_/CB_/KH^/J* MGV6_5MV7E%=^B'C4>.8YXHH9]",( #7_JX;H2Y"XZ*:&5,LT;^U MU=T4G7:WWNJU>BMFR'MZCO? D.[.3GUK9WMGQ0PY3:4N"W%.Z=&XI?1XL[Z] M=3"I0->(3+H*XW,S_'<'_H\7;_\#4$L#!!0 ( /E RU#79(1?"A@ !S$ M 1 Z?/S/ M9.BC*Q;%7AA\*LA%J8#^L__Q_S#^Z_>3(U0+G?&0!0DZB!A)&$777M)'YY3% ME\B-PB$Z#Z-+[XI@+.H\28)CYGPJ])-D5"F5KJ^O MB_!<[(57)2_PO8#Q&9>2B 2Q&T9#D@!$2HHDZU@RL2H7TG86ZE^KQ3#JE63+ MLDH3WE=6J#*!]BZ7%^5?\Z*4>;."$SOR9X."#[Q["TOR;?=\&@OMBBJ\Y?;1+/6I_$WD.@ M@K)RZ:_FT:G39T."%\94\4G0^U1@ 3X[+0":&:'['XI2P0/^%["S@H M\IRT_TERPMQ/!4]V'(=2Q[)MW=6(*=F.;CCEM;+1_*;$P%%) A M[YIYE2HP)>6,^=DGO0+R*#1)U:]3NQ9>'2DG5UVU.::#^M7%H35H#VC_8M"3 M+\Y;7FO04[N=D\M6K:XW#R^\9NV+=E&K*QGQRI+;][$ZK=\Z[6.O\Z MZ [@7Z4N7=2^3-J=WX?=055J'WZ9M(9?E.[@<[_YU92.E(MI]]PQ+CI?^\W! MYT&KUKQI'S;UUF%STKWQ+R\.&U-H1VEUO@[:M;-)<]B\HH>?/?OPS&B??YDV M;[[(S9OJ3?.F>].J]?3FS>5-Z[PKMSM?O>;A'UZKXRBMP[.LSE?H2P\N.J%^ M46M ^;.;)O37&C2E=NWRIMUIRA>#,[UUWKCN#AMRZZ8K77PU;XXZ]:1Y*DV. M.M5OBB8Q@Q #VZYK84US'&RIDHW+MNS*FN7J3MDM[+O$C]G'T@(*UXG1>@ 4 M-ST E$;$;P243?YDTQUF'\.L.H]9XB@RE7476XZB8$W2X)>L2UAV-9DHU-15 M72_L2R!75-W0R\8]])86F3=B+HL8R)SX 9G#I5@E%K()" )F5Y)0-)\*L3> M<.1S027>]2-.'POBI3B)*3116FPC[?^VTVP,<3B.Q).0VI6,Z%+*^!&BRQMB M@N+R)X_R9]=C$1(#8@\JRH/&GXL O%MY/W^UV/H(X!O2_ D$>934P)[8YX/" MDH&YQ+W[;39,NJ1H_B5_SCLI+0 JA^H,C*4Y85T"D9[*=0'.QTR*;W)AODZF M"_J,FSP532F6]5'RX=JC2;\B2]+_?RB(-W&N*#Q@3 MW^L%%0<@R"+>Q++:WZTW)%'/"[ =)DDXK!@P+F@I(;;/\CI9"9^Y286,DS"O M(@RX](T=1@ F[(2^3T8QJ^0_/LSUQ^NGSU[ R: B05^Y>DQM RSZS0!C645@ M1 &;!#"0T'P\&=R**=Q*";W_T3*+DO2=[PN52Z+YM L8.(?R%X7C@/*IAE$EZMGO%%W?R_]'4E%Z?V_28#4GGD/\[%T*ZAQF&>"A>43# M,0?[;Y+X[\.(4.H%O13P,G2?OT@!+Z>HNIU"24!O):1S Q?#VX@X224>#P&C MTYR"\EHK3C;]EH_9!5["+AEZ_K3R[XXW!(G88M?H)!R2X-][,9B;T'7DN6G! MV+MA%=F$B8C'ZQ3296A'4$,&>5D1R#IK-3KU&CKM5#OUTR<0^(9/Z[1^<';2 MZ#3JIZC:JJ'Z7P?_K;8.Z^B@W6PV3D\;[=86S%5:;:[G).X# 2=AL(=JQ8,B M>'^Z9MV;WX9,0GMX$O_Z33:D#UN E!4)\'/[I)G-:7U6:QX?2#VLES16)S-C MM=;5FS4'#,\N&*EG&O0Q:1[6H:TF&*I][V)X<=FN?;ULW7!C]:M&__N'?Z'X M5_9@=-D:7%ZW;L[ Z 1CM].3FIWZ=;=#^]T;,%H/_QA>#+_ >+ZH3=FN:CK,8= M()Q/ZJT..JD?MT\ZKV=>Q^,H'I,@04F(3IG#XS\IZF05A1&2]7?T??HB=%'2 M9[S0./(2#\90GSA]<'$8JCH)@L^RI6H[,GW1^7#_AJ/BA(W"*$'O\F=&P,-A M<8+8%8_.1N(SH^\K^=0W8E)+:!0]NT)*8YU0>Y)4*(!H""WV*9E. 4XL>$AA M'0M?L9YZD&],5L:41!;N.:QL&M:A1!E_WCW' MD+4GHOD[#;99]MW:8Y$GK.?%/)60M.#+&^,1L.[4;Y)J,Z4LN]C5M#+6;%;& MA#DR/+IERU(E37)-\/3&(Q8%XQ@=]PF((8>-150@WDLIKA$XQ<=Y9_/(<$6V M>E>?$# 7./%PQ13-B :1&,4CYO"P($5>@+PD1F!@@)Z*WB^1':\JRJ7)^H]% MN12S6%;U%:-<3_IH%F6MO)Z&5X_+/>FCIJX+%G)1-=7G"27F ;PD'%64T606 MT,O(DK]ZUA#C:A'$.<99J* 4%?U>G>SE8QR6-;T1 NF>7I36HQ?GC$L>7^49 MBH2-HO"*R[Q%ZS)5G"#QPP@,'W6JLY0>50S'=54)&[IF8LTT76R5 M31D;AJVJKFV"D-7!36(^N093_WY";R';DO'YC(.-]7)PQD$_P\/SC/8(*ZS, M4HN".USC]N;MS9%L:A' N]& M/+]_60MH'3A_=?@]"(=#+^;KKQ$W@5 JK!_#W.8HYX>0#!WLN/J[6&\43XJG M150?COQP"FR]J+!1*RRN3@$;I4:,M:^P>L((?Y!CK%*OH0)L#/CGV3& M5RF-6!QG_QR!$)%W)OQC)OS-?/3(5,O@ =LNELJ&C375 J?8-/C2<-6FIJH9 M)C$*^U99UM&?;(K.>4:]>K4\C+0!FO7-FD^_*MR[A L/X&<[ZH37P8X'5^#! MN>@4(533; /K)F58LS07VYHL85EU"=-43:R?A,[EE>?[3PWA[CCPS7"@ M\(/;T7$47GEB'^".#1]EP\:,#1W)=%UJ,NS8BHXUG:B86+J#F:)).C/+!E7M MPGZS]OKY[U6YER_,D\=AG!#_PAOM4ILKJ-B(_J$^:,$^^* MH;;K>@Z+5P\E;VV@9$>6FT26H%405RM;$@>]MTWSNTL:-Q7V6[96>L7YW"YE M_M=OIB*7/\0H83X;]4$FH$#D6_9X(LT?-BC M"N#86OONIY: :]\LW2X3D]I8HXJ+-4=3,'%M$UMVV5+XZAI*K,*^*LEW3;3W MS[_+Y18K1R&(JV-.O5N\LN.G,"-]Z5#9-9K3!!U='(![UK\Z#?ULUKV7:(SV$$%);MAXC$XF%X M)*F)#4K&1>DF2XIB'L5"/HGS_7MW,[X_<2[(9@,I)>;T[]S^TW3O"(L -J/[ MVUB1K+RSWZ-LV^K\7M6E4-OME:RXX(O:A:\EIV<0!] MJ<]T;LLOS$SS52P9^GEO8/*C./0]BGYSQ7_YQ]Q%N//U63/:VMHSV@(*7RHKN-IJSX M#$M+RF\A%EO9CDK!<"Q7=Z 'K_L>O+E5E@L(WC[A>1N1>LT,N]:43&9#367% M%G)Z*]W!-!'#DRZMPZ;:O.GIW4YCTJHU](OS/Z!,XP;=Z\ M>VPD3[I(W1OGIEWS^\U!76H.?+\[!)=QT-2ZP[K<4K[HW<'EI"N;D_E50HKK MZ&6^J^B=@59+1B$3H MBOACAD;\X,3^]_:@;97\W7'E3W-EIH93+;QCR158W;>?Z,P\J;.UY)[^: M86^7%Q%-!D3:&F:F96/-IB:VRX:.;<*(9!HJU34'/),^0RT24_(W.O1#F_BH M2:)+EGR7B5]==NV@SYQ+$<4BHU$4CB*/;_"RPPFRF1]>\Q@A_\@CB6F,S,1_ M(M?SN4_GQS??F&S:EBD;6+5M M$VL::!7+I03+# Q!HC/-5A5.7E99TSXL4QT_3F2NNW8BVZQE!4L&F=$CL, \ M02ZD9D[&/DO97%/T3)O<.524GR7Z3BZC@\\G2%&E(A1<=OK7I@)B)\B>)LA. MP>=P /M!KPF _5FY-B3?V;;B@N ,_!)M$4K"E,XZ>RR.#,VCIAED)M)JU1 MBOT$6[PF(79+BVB8$>,2"29KH&&4.2&V,FV+\ M)AYQPCWWN:*VZ[[%U5;R-ZH93.7'VUO$<+%F2!2;JJIAB;H:-?FU?-)RFVPK M) 7@&SMS"%_-[I$UBOFZE/1I)>&15MB)CSUYV0JAL<+EC\(%SHO[(D#M4?\0&V^UG2.H!0;*P\T M^- -'[.6.5W=UIMKN[@F_?UJ9'VZ);:>X?Q0H/P@Q?C;$_.3;Z:FN8SH-C; MS\4:D31L45O"NDV(S13)<"1CN\7\EDFP[12[[G<$*=^M]:!4]N[EN/H@1 *S3N.F2@%XB'+I/$+LSV1<$DO$>6\+_KRI[QS<>LYE]\!3 Z^1.S* MBZ$>2'(2.%R*$ M>?/"YB[,WUU.^IR7DV9 5XW;E2:K7/'Q]&JC,&7?2L1\PG>MS]_">^=^WL+# M-8D=A_XX81\RX$A/O\@W_=N/;A<:]1BV(T8N,7&![BO$OR;3N%!Z[NN#-T22 M+]GKU4C8$"E%24X%';>,?):O2*@Z?X^]3/:"9*T!;X;Y(WR-8Y;$Q9^X+F:> MEN9X9#".$\]]N4Q[0#-W\&UAY9>-H3X/4/H'5HTK. :%$K%D MY.STO(GJ7*2/(E"(,(JCHP/N4(@!W/V:CV1/# 5>\<:$'@;%&3%PG>(QWQ?' M5]$BAXR\A/@/];(PRPY7W213J7G[\_J6H%," @[&CH['$2A74/[57L12_UQH M]K-3=!Y&/FTR4-K')$H"%MV;RVV1VW[X77,456%8/E+,%$<+HYMUE-7<3T/U5)0C RGY,[N.,. MB?L[_#P;?LYF<2S@W&&<(VC&$HOH$:*';_T4.(7/?"44\.$5R"@43V.N0_@F M63<$=*52X1:5>X*]L]O&0!SZT[1Q8;1P(>".(Q&LH>R*^>%(%!=QNHA;[S K M8.+PF3*"Q&/@J'833JPU1!VKIC<63W\7@XXL3#"X!% MS>6!.*@N%M6:T]#V0R=KZ)J/%_0[6Y 1QU%(QTX2[T3$LY-@9X[ KH'1D\V#\5]590P/."%!F/PA3[Q.E[ M0%Y"K4!5!PQPX@5S9,:;8'$2!F*OLR]T![3&Z\:YBLH(-&^$?\OI8T<7STH7 M"T)I3FN(>PM9PB, 8!IDG#UG,# P3N:,)W FN09* [IS FUVT,S!.(IXQ>P* M7W[*?Q@-4;:F%^K!FR:9(BTU'S;5UE5D15>L=2,%@,YZ(5?GE,5.Y(WF%RX_ MK$8$VWCP/N"F+(K'PR&)0/[3$,;& SY@# K( ZL!^^=6<%[M[S$ :?Z*RM08 M!?O6G@*7NH!N?DQ#QJ=SRBO=ACFOPM*%V;'0-_PB!Y*F B9]S_:2O(6[Y/%E M+&[$A+'?(1!9PE]$&(K7RJ)2:;1*> 2J=(=>7@2UOU JK)\ SP)?'(/'+85K M<#1FJ1IX9EYF3F9^";1+,X(<<^8G=GC%N.L"2J9/KE@FU8<,#1D)Q*%2G)[M MF<@?WA,M3^3\#9&PW_/YS2(_%^GEU('Z].-(WMK?S5+72XBI+6SW.K_J_MEB M0=L6^%E0-&F@A' [)!:V).-1C2R.DT=5ECO&.TOR^8(08%",IK.4^2)"X 4X MGH$7]SFV>/H]-04LJR@+I<+#4ZD9@I;C4K&81 MP&?/#2D >WXO$(O%L.6U CH#_ 0FH\))!U63+$;(% M$ED4['8)0WR+%NXV\_@4=SX!*&4943(%MG*3+*++$Q_\6Y*JO>^-C,0+(3>; M96&/^1S-+$-8O+^T9DT)Y+/!W<^ELB&+WM.J7!O,9H! \T#&O>T%8_\BC!& MZ*ZFM.:Y\-4P[X*H0K*DS=B6Y[J<\ KL!;Y&$+E1.'S,5MC+]B,D::JJ(1:O MHK]^/SGZH=C01BRH7+Y">('+LIS>IB-:V:@UH9M_A/Z2B,YIX[!5[9R=U$]W MD9L7W1 ])]3G_*-9X&:%O65[#VW&H&-_BAPBTJ9"YJ6W'V3N3PR$FBZ*X,EX MF_6)[W*WC3;N6 !5:_W@50(: M6))R>1T'_BM%55G/30)*43>4#;Y)X*'-%_P4T)\Z&?<%CN*\PT;+;_O;'BB^ MQ(FFIV?']9/6V2DZ_F_UI%D]J)]U&@?5H].]%+Z-UD%Q*8P?NQ@^),P+,4E M=,A7\D93=%I$QR2)/.?RQ2\J>2.VV0Z*6PS%AV\+R.:V=8)@)P3>&/GNH/CB M4'P1-Y<%7ABAKY[#,$]W>33?F7/0]Y@[MX2E[;I0*/K9&QYV>8H?#^RJR_,4 M)3ND4_BGGPS]_?\!4$L#!!0 ( /E RU#NJ!$BI0( !$* 1 ^1"(6I2::TJ3^3N,'S[ MT&PT3!,:O2\F8XB#>'0VPA!D!(]R"#")TPC3:! 20F(:T=21KM1$T054!!EA M7$U6:NHMM*XGOK]<+OO+85_(PA\$0>@_?)I_ZULR_KCCO4IEV?D/?3N= M$@6=NVIJON-N#"!YH_I45+Z5&T1!XB&BM61IH^%:R.H*NHU_$=#2I8S MR$S*2[!)W7'8FM9$%J _DPI432B\8=%9#R&;"U;50FK$#Z Y4:F3UBA<$%(; M:)C@(,3#T$/K#,X%)=J518MQZ7@1Z$.I56?!&ZK^2F6>_VHP6SL3)DGBKVRJ MCX9QN#/.']LA#@>G+;M+Q+C2A%,X96WSA3O5MN#6Y1? O8/AS;C=CGH1UAJ[3+;' MK+][SJZ_M\YB9U@?\[/>3U!+ P04 " #Y0,M00$2E480! #2 @ %0 M '-U<&XM,C R,# V,#E?8V%L+GAM;)V2VVK<,!"&[_VLN3#.K;9W4"W M% I;"-N&Y%:6Q[986S*2'#MO7TO-@?1 H3<2,_/-_#,C[:Z7H495AGL418RSG&:]\T5[(2^F.BAE MZW#2>',?=-:.)2'S/(=+I?M0Z9;$E";DF0Z>\.4W?DX\'15%07ST!37B3^!: M-B+W7T_?> <#PT(:RR1W D:4QCM/BC/K=_[/OM!?"6?A9PP[%XYBG$3A8NK@ ML$'HYSJTZN$,#7+W[?G+&TDSC:#E9$*N!N( P8 !4 !S=7!N+3(P,C P M-C Y7V1E9BYX;6RME%UOVC 4AN_Y%5YV.V/GDP0!E<8T:1*3)K:JO9L<^X18 M) ZR3:'_?DX*%$JK2FMNHOCX/>]YCFV=RX:O98/ M#.-9ES1O-H]:KDJ+ AK0E[MZ'(*?9D$QPG'"!(Z2),)I4,0XYD7&113F&4^^ MK,8QI#2-1A$&*AB."J"8I7F">1+XC+&4)SSO3"NIUN/VDS,#R#6G3+><>J6U MFS$AN]UNN,]U-6STB@24AN2H]@[R_95^%W9J/\LRTNV>I$:^)G2V/KG_N?C- M2Z@9ELI8IOAS 5=>V%/B.4U,GC:=U,BQZ?(7#6>VNYYW6T!O*MH5/LIP&\)^ M@$-_N#?"FPT0>CHYIKEN*EA"@0Z_M\L?UZ1262)D30X:PJK*$7<.]G$#4\_( M>E/!,59J*-ZD/[;<0L4MSN?6C7R8J70@FF]SP"X*JGW@/3*^YOYQYI,7%E"P M;65[)+[V[I6WJ9GL\X"OK'N@[8QP#74.ND_4"]\SSB/D2\+6TFS= U);,^1- M33J\>>/F\"^V@O?17++"[4"E"Q8N.7!H:WU?R2PMZ $ M" ]),?5DSGD1AT!C/T\C4?AY5HA01 'E(QKZ(_[W@FE"+D;S;/ /4$L#!!0 M ( /E RU JD#Y0@@H -)> 5 &UL MS5QM7\'Z?MF=J6HDA$"=-G>ZN>U.9G/;3IM.[^S.CD=O)$QMR M)/]^)6PGQH"-P*9\::@MSGG.8YYS=$#HS>\/B[GS4V7+.$W>3N K=^*H1*0R M3J[?3KY=?0#AY/>S%R_>_ V O_[YY=+Y(Q5W"Y7DSGFF6*ZDWCUE\?9,[R$7N[K?9:T_!D*(H #YA$F!", A1 MY -?1%1(['$JR,OKU[X*W1 '&"A7,H CY0(6<@($09 Q%@HB>&%T'B<_7IM_ M.%LJ1P>7+(O_OIW;;D9/UL,?*N/OO6(T MI)1.BV^?AB[CNH':+)S^]>?E5W&C%@S$R3)GB3 .EO'K9?'A92I87G!^$)?3 M.,+\#VR& ?,1@ AX\-7#4D[.7CC.BHXLG:LO*G+,WV]?+AI=TJD9,4W4M?EE M/ZLL3N77G&7Y)>-JKM$7UO+'6_5VLHP7MW.U^>PF4U&]V7F6E:P:E-2@A,2@ M_*W)V;0'_"/AS:M8CP"N"/?CL3#NX_3CT>!>Z?R@3@]XRTUOR*L+ZGTBA[IV MGUSUAGYZQ,>Z+-*X+)[=;$&>FP\N]=':C3&T)YD6?M:I>PNJ>LA5(M4J M6Y9,.[%\.]%',ZGBV?9>S@+%))0T! +Y'L"!KP /D 22 M1)&/?%V5H#?+GR[JF4K MZ\;_X63 QXF%K'E#1K-U#*]R\1S=5O,ZTJ6KE:F MOH73A"W4\I:M3] PS41@A?QL#=(IHWPS?0ZH"XWSTY,S'Q4OJ2@AF9NI0)KM MQIZ*P[$_:VNI81>!+Y5X=9W^G.IS-0&0F@-@#H +UU.#WYKM3BL_X+ML@Y9E MX@#7ZQ%3D>K9SFT.2K2;V6'+L/*TY6^_(E"[G3AI)E6F9[ U(92NP<^9,K;T M)%>9>>R5D7_V*8I4-N,11%(0"B0*(,"4"\"IGE-1$E(6*8@AIVWUW.QF;*+6 M2('8@NJLL#H%V/;:WL/K88$?AZT3J[P;459B/\Q##\7O,3Z8[ \'N*W]%J/M M$\#[)(_SQPO=Y&:W:5;D$]UWY-K379)GC^>I5#/,".6![P/L>A' DG 0$LH M\J#D(?*5B'C;3-#"W]A2P@JR4\+\TBE0:YJ=-7+'0&^?(-KP?CA3')G-$Z>, M8Q!IE4 LZ.F12=IX&2RE6(2\G5ML3NN:9-Y)J:^FY;D^_)1=I??)#(:"*3= M0%%. !9" 2:) # 0D>>S0$BB[!)+Q<=(D\D:YTO'(#47O\%JFSVJA+;-&+UH M&B9+V#'4(2TT:B_SK^D\%G$>)]=_ZM21Q6P^\P-" M%:<0"!_K)@)R":B+)8@4#B'V?1RPJ*W"J^;')NYGA,X&8GM-U[!W6,[].#FQ MDFWHL!)P<]0]M%MC=##9-@>TK=@]HWK6Y/6?RSA1<$8D\UW)BID^UG-^79I# M1%T@78^%$6-!X(>=JO*VE[%)=[?JK \< ];YE%C/[.N(M:S.7>D:N#ZW9JI[ MC:YCXEA5NF3[U]3INO :*W7MX ZU6HF[3%M]_R!N]*^K/NI??,:H3Y3K8>#J MEAY@Q#W /"6 %U$]+X]0@$7K6_AU#L8F^@U&9P/2,2@M2G8=B2V*=D]J3EVV M[5BQJ]Q[0N]3N^O,#E>]]P15JM_[QME+V,S9WV6*%?>*0HI#)BD%^F^H)]H( M 72B,^"<_V[@_<]"=B7"6NBN*PVG%EY;!NRD5Q=M'^V5[ TG MOKHP2NJK'="U9SU7B38TOTBD>OBW>IQY@>>SD'$0D4B7/H]*P"/, (),N![T MJ/*Q7;^ZXV%L]1=(MOVISWH&:8W;<],AYZT(?K>_>BN MW8%[T8:PJGUHT\"N;]2<2 M T&8YP9!2!"S?#C4X&FD\M9HG3)<9X775N9-!+>5^Q%H&T;V]HQUD/\!-GJG M@2;[ Z># V%6T\*A$[JFAP_Q7*TO6!IXRH.!U!G!U?-M& @0$AF"* @4PT@I MC"T+_;/QD28! S"SO"M5X:VMT+NQ,8RV#;83J+D:<(B\2;56Y;7ALBGQZU\N M:Z_&$E>'E=B5@1.KL%WP5@*LB[2'^$KF!A->71#;HJO]OFLI?+]0V76<7/\K M2^_SF_-T<[F6B=VFMMSYPE=T;8K7@[A_>_<$M M1/PJSN>Z_N( !S((@.M!/2O&@@&FY\( X9 'H<\9;?_D9]?XV$1?@'+2R('H M[_P?S@:N_1/;)_8.2[P/)R?6M2T=G1[5[L9]A,>T3R8'?T2[&TS=X]G*&'N1 MOM,U7YJZ_V'.KF<>H:Y+L 0<^T0KE#(0XB@"BG/JJ@ AW/[-R)+ELX,)L#:,;?75#["7GME*8O[Y)DV> M[AH1\\:BGAI3%XG572-.,0%<,<0XXCYQ65OU[1H?FP +?$X!T/IF<86XPSKL M0\>)I6C!A)4P<:PUR+OF?\TRY(8@&U,ZYEUC(A=.9K MX'30EJKNR:"6B6.E@K+Q7Y,(:@-L3 /UHWMO17*Q7-ZI;'OC#*A[9B2D!UP4 M2O,NH6^V(< @@'J>H*!P74PZ;DA2<3:VA%#9;6.%^#B[DU2I/IP;CDG@B3-$ M+^[Z;%C22,KQMBVINOA5FY^WWC^LUL/8I/BT1F*%TM$P'8/3?JU(F[@2TMJPZI;8U(_L&LW_D5=Q^:%C20OWFKUJ?(B[FJ.7$_WXG08]>' MWKN[WC$[<%]='U2UHVX8UR3A;=XO]='9B\TG\6H3]+,7_P=02P,$% @ M^4#+4'[K&V2G!@ K$E)J%#:=)A'MHP"9UT>K.CEZ/%DUU[1S8!OOUS;*"! M0%H/ZQF<&^.599]S_OHAZ1S[U<]7Z]7L,Z:FK*O7N]D>VYUAY>M05LO7NW^> MO06]^_/!SLZK'P#^^N7]R>S7VE^LL6IG1PEMBV%V6;;GLX\!FT^SF.KU[&.= M/I6?+"U"Y#2#S7(+F48'RT?@@A3,^ M_VFYKU S+0L)R((%&9&!U2X'G_/,6JM][EW_T%59?=KO#LXV.*/@JJ;_^7KW MO&TW^_/YY>7EWI5+J[TZ+>><,3&_Z[U[V_WJ4?]+T??.C#'S_NH_79ORJ8[T MV&S^U^\G'_PYKBV45=/:RG<&FG*_Z1M/:F_;7O/_]&OVS1[=+[CK!ET39!Q$ MMG?5A-V#G=GL1HY4K_ ]QEGW]\_WQP],-A<;3-5%L^?K];SK,#^J"8=3N^S< M[6]OKS?X>K,]H8;; M9W36GN<+7K58!;R)\<[*JO8/.JTZA>MT=^?*.ESUK8N Y:)_\J%KVF1]N] Y M$P6S$33+/$@N SAO"_K);>$++85@#T/OW&[([WY &O1[R_KSG!Y, Y.9[@2Z M$V#9[7#\^,CHC4+/\_[NO_",^BY8%+DKK %C! >)T8*5(@.5Q9PQQY%B&\'Y M^S8?^GY_? ^3G]4I8*+)Y,ZH3?[16#\$^;;'?&,3/0C\>;D*=W=WL\H8X];6 M(^AW,SCD[NZ,HHZ8$H:3F['Y9G!]9"U-L=CW'&/<3S&5=7A3A5]I#EXH[E3A M"D:Q=P$8'D 'F4-AF>:9"BJ38]#[I/%!)/#ID_!\15\8B3=56[;7[W%9=DI4 M[1]VC0OKK=,V9" UDR"=0UHNC0"KT#(ND=;5,8AXRO8@(,1T@=A:STGP<$Q[ MN+2I4R_\!](?C^J+JDW71W7 !?(0$;T H:P&F6D+3O ,LF RX:2/JA@/CW]U M91 M!4+*%6B$"6:5 M))@N*-LS"N* M0SM$P4<#XAM.#*(CGSH=8R@\"50.0Z A:&[_4(*'V:+P6G%4'% +2NLC^>\$ M*<6C*T1NE K1CX;)$PX,0J28.B+;*CLE/([H]%TZJR\KNH;1<%H0^\*/]);. M1,X(>!5$5@@CHQH;CB_F!Z&AOQ,TGJGJE,#H]TOOTFFJ/Y>5QP4WM@@\+R#G M.>5>TM(J&8R%R+D.A9#*&S,V'5_Y, @1\YT@LHV^4^+DM&Y:N_J[W/2;ZDQY M1OMJ!CDZ"Y(Q#[K@$@1S6.2&LU#@V)0\\&!8"8Q])Y \7]P71J2; \3VIM, M"V7>O1$ *6C_)&64)$708 T%E-E@?!ACZKAONWJU<(8Z9SA&C)?D.,96K#<20@\1A&D#44V1N;YP.BPX9]P M&?/Y$DYD GASY<]MM<2^6H],.*F$ \6=H55,&-!H&2!YKQ0STK!LQ$G@ONUA M)$RX)>E7ZLJ4)[G=*A5-I5PLN"JVT%V =A2"9%MT+ MW@@442PP.N']&.GC8\O#:)AP97)+,5\8A=.$'<=8>>R__^@^(TKO(OE!JU[( M@C86/!,4!<\H"B#$-CPI7)D<2=%B+'37.!Z7XL%H5T M&9>4&HE(L: @X8R)1NS/+2__!B&RX2KE*,*/8E*Y9LUIB7-C+^E M^K(]I^ VMKI>4-ZLC9,.>,@LK93=QT1*9$#IM XNU]%P.UJI\DD7AGVD-?E: MY?;ROC EA\1YZ%A_N[++1>Z=MF@U&&<8R)PC:$Y[*9U;%U"C9'R,/<@#H\-( MF'"Y\OD23F*&."+/DUT=TR1W]3^\7B@?"FZZ*8!?3[& MM[M/&A_&PH0KE]M+.AH3K^:/1#RAAH.=VPO=H?M(_V#G_U!+ 0(4 Q0 ( M /E RU#1?181,@P -,Q 3 " 0 !E>#DY,3 V+3 Y M>#(P,C N:'1M4$L! A0#% @ ^4#+4-=DA%\*& ',0 !$ M ( !8PP '-U<&XM,C R,# V,#DN:'1M4$L! A0#% @ ^4#+4.ZH M$2*E @ $0H !$ ( !G"0 '-U<&XM,C R,# V,#DN>'-D M4$L! A0#% @ ^4#+4$!$I5&$ 0 T@( !4 ( !<"< M '-U<&XM,C R,# V,#E?8V%L+GAM;%!+ 0(4 Q0 ( /E RU"">"<7"P( M 'L& 5 " 2&UL4$L! A0#% @ ^4#+4'[K&V2G!@ M JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "supn-20200609.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "supn-20200609_cal.xml" ] }, "definitionLink": { "local": [ "supn-20200609_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "supn-20200609.htm" ] }, "labelLink": { "local": [ "supn-20200609_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "supn-20200609_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "supn-20200609.xsd" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "supn", "nsuri": "http://www.supernus.com/20200609", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20200609.htm", "contextRef": "i1cccddc9bb5f4a80bc56c7778b063f39_D20200609-20200609", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://www.supernus.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20200609.htm", "contextRef": "i1cccddc9bb5f4a80bc56c7778b063f39_D20200609-20200609", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity Filer Name" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } XML 14 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 15 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 16 R1.htm IDEA: XBRL DOCUMENT v3.20.1
Cover Page
Jun. 09, 2020
Cover [Abstract]  
Document Type 8-K
Document Period End Date Jun. 09, 2020
Entity Registrant Name Supernus Pharmaceuticals, Inc.
Entity Incorporation, State or Country Code DE
Entity Filer Name 001-35518
Entity Tax Identification Number 20-2590184
Entity Address, Address Line One 9715 Key West Ave
Entity Address, City or Town Rockville
Entity Address, State or Province MD
Entity Address, Postal Zip Code 20850
City Area Code 301
Local Phone Number 838-2500
Title of 12(b) Security Common Stock, $0.001 par value per share
Trading Symbol SUPN
Security Exchange Name NASDAQ
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Amendment Flag false
Entity Central Index Key 0001356576